Researchers from Massachusetts General Hospital (MGH) have shown, for the first time, that blocking the action of a critical protein can improve multiple inflammatory pathways in patients with the metabolic syndrome – a cluster of symptoms associated with increased risk of cardiovascular disease and type 2 diabetes. If supported in future studies, the findings may suggest new strategies for improving the cardiovascular risk in patients with the metabolic syndrome. This preliminary report appears in the April 24 Archives of Internal Medicine.
"This proof of principle sheds light on the physiology of inflammation and its relation to cardiac risk in obese patients," says Steven Grinspoon, MD, of the MGH Program in Nutritional Metabolism and Neuroendocrine Unit, the report’s senior author. "And it’s the first study of the medication etanercept, currently prescribed to treat arthritis and psoriasis, used in patients with the metabolic syndrome."
Metabolic syndrome is a group of symptoms that includes abdominal obesity, high triglycerides and LDL ("bad") cholesterol along with low HDL ("good") cholesterol, insulin resistance or glucose intolerance, and abnormal levels of several inflammatory proteins. The occurrence of the syndrome is increasing, and it is estimated to affect more than 50 million Americans currently. Also called insulin resistance syndrome, metabolic syndrome increases the risk of heart attack, stroke and other cardiovascular disorders, as well as type 2 diabetes. While there are many questions about the mechanism behind metabolic syndrome, current evidence suggests that inflammatory proteins released by abdominal fat may be an underlying cause of the increased cardiovascular risk.
One of the key inflammatory proteins released by fat cells is tumor necrosis factor (TNF), which is known to increase insulin resistance and the production of other inflammatory markers. Etanercept, marketed under the brand name Enbrel, treats several inflammatory disorders by blocking the action of TNF. The current study was designed to see whether using the drug might also reduce the inflammatory effects of metabolic syndrome, as measured by levels of C-reactive protein (CRP), which also has been associated with increased risk of cardiovascular disease.
The researchers enrolled 56 patients ages 37 to 54 who met standard criteria for metabolic syndrome but did not have diabetes, cardiovascular disease or any other inflammatory disorder. Half of them received weekly injections of etanercept and half received a placebo during the four-week study period. On each weekly visit, participants also had a physical examination and blood tests for levels of glucose, insulin and various markers including CRP.
At the end of the study period the CRP levels of participants who received etanercept were 34 percent lower than those of participants receiving the placebo. Levels of Interleukin-6 and fibrinogen, other inflammatory factors associated with increased cardiovascular risk, were also reduced in those who received the active medication; but levels of adiponectin – a factor that reflects reduced inflammation – had increased, also suggesting lower risk. No significant side effects were reported.
"It has been speculated that blocking TNF could reduce systemic inflammation in abdominally obese people, and we are very excited that giving this drug had such a dramatic effect on these major markers," Grinspoon says. "We were surprised that it didn’t also affect insulin resistance, but that could be because the study was only four weeks long. We’re planning longer term studies to get a more complete picture of how this strategy might someday be used to reduce the risks associated with metabolic syndrome." Grinspoon is an associate professor of Medicine at Harvard Medical School.
Sue McGreevey | EurekAlert!
How brains surrender to sleep
23.06.2017 | IMP - Forschungsinstitut für Molekulare Pathologie GmbH
A new technique isolates neuronal activity during memory consolidation
22.06.2017 | Spanish National Research Council (CSIC)
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...
19.06.2017 | Event News
13.06.2017 | Event News
13.06.2017 | Event News
23.06.2017 | Physics and Astronomy
23.06.2017 | Physics and Astronomy
23.06.2017 | Information Technology